- Home
- GAME vs BOLD Comparison
GAME vs BOLD Comparison
Compare GAME & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- BOLD
- Stock Information
- Founded
- GAME 2011
- BOLD 2018
- Country
- GAME United States
- BOLD United States
- Employees
- GAME N/A
- BOLD 64
- Industry
- GAME
- BOLD
- Sector
- GAME
- BOLD
- Exchange
- GAME Nasdaq
- BOLD Nasdaq
- Market Cap
- GAME 27.2M
- BOLD 24.4M
- IPO Year
- GAME 2009
- BOLD 2024
- Fundamental
- Price
- GAME $1.90
- BOLD $1.17
- Analyst Decision
- GAME Strong Buy
- BOLD Buy
- Analyst Count
- GAME 3
- BOLD 3
- Target Price
- GAME $3.67
- BOLD $4.00
- AVG Volume (30 Days)
- GAME 7.7M
- BOLD 283.9K
- Earning Date
- GAME 08-13-2025
- BOLD 08-11-2025
- Dividend Yield
- GAME N/A
- BOLD N/A
- EPS Growth
- GAME N/A
- BOLD N/A
- EPS
- GAME N/A
- BOLD N/A
- Revenue
- GAME $99,579,536.00
- BOLD N/A
- Revenue This Year
- GAME $6.08
- BOLD N/A
- Revenue Next Year
- GAME $21.94
- BOLD N/A
- P/E Ratio
- GAME N/A
- BOLD N/A
- Revenue Growth
- GAME 77.06
- BOLD N/A
- 52 Week Low
- GAME $0.50
- BOLD $1.00
- 52 Week High
- GAME $2.87
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- GAME 75.08
- BOLD N/A
- Support Level
- GAME $0.73
- BOLD N/A
- Resistance Level
- GAME $2.87
- BOLD N/A
- Average True Range (ATR)
- GAME 0.22
- BOLD 0.00
- MACD
- GAME 0.13
- BOLD 0.00
- Stochastic Oscillator
- GAME 53.88
- BOLD 0.00
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.